In contrast to CPIC, our findings challenge the recommendations of the ESMO Clinical Practice Guidelines for Early Breast Cancer in 2020, which recommended against the use of CYP2D6 to inform adjuvant tamoxifen decisions [24]. This evidence concerns the gene CYP2D6 and breast carcinoma.